Ariad Pharmaceuticals Inc fka ARIA

[BTH]

I thought about Pfizer but they have Bosutinib. And, aren't they trying to get that drug right in there with Sprycel and Tasigna? '534 is the only one that gets all the mutations so, technically, all of these cos would want '534, but, Ariad, IMO, would be negligent in doing a deal with any company that already has a 1st or 2nd line therapy because it will be taking a back-seat and only be used for T315i indications IMO.

Personally, I wouldn't mind seeing MRK get '534 because it would give a lot of takeover spec for the stock.

I think Eli Lilly tried doing a CML drug with Supergen (maybe?) but it failed (I believe it wasn't a TKI). They could be a considered partner but I wonder if LLYs CEO hates Harvey after all the patent BS

I still think MRK or CELG